Jongsma Karin Rolanda, van de Vathorst Suzanne
Department of Medical Ethics and Philosophy of Medicine, Erasmus University Medical Centre Rotterdam, Office NA 21.17, PO box 2040, 3000 CA, Rotterdam, The Netherlands.
Monash Bioeth Rev. 2015 Jun-Sep;33(2-3):167-80. doi: 10.1007/s40592-015-0034-y.
Dementia is highly prevalent and incurable. The participation of dementia patients in clinical research is indispensable if we want to find an effective treatment for dementia. However, one of the primary challenges in dementia research is the patients' gradual loss of the capacity to consent. Patients with dementia are characterized by the fact that, at an earlier stage of their life, they were able to give their consent to participation in research. Therefore, the phase when patients are still competent to decide offers a valuable opportunity to authorize research, by using an advance research directive (ARD). Yet, the use of ARDs as an authorization for research participation remains controversial. In this paper we discuss the role of autonomous decision-making and the protection of incompetent research subjects. We will show why ARDs are a morally defensible basis for the inclusion of this population in biomedical research and that the use of ARDs is compatible with the protection of incompetent research subjects.
痴呆症极为常见且无法治愈。如果我们想找到治疗痴呆症的有效方法,痴呆症患者参与临床研究必不可少。然而,痴呆症研究的主要挑战之一是患者逐渐丧失同意能力。痴呆症患者的特点是,在其生命的早期阶段,他们能够同意参与研究。因此,在患者仍有能力做出决定的阶段,通过使用预先研究指令(ARD)为研究授权提供了一个宝贵的机会。然而,将ARD用作参与研究的授权方式仍存在争议。在本文中,我们讨论自主决策的作用以及对无行为能力研究对象的保护。我们将说明为什么ARD是将这一人群纳入生物医学研究的道德上合理的依据,并且使用ARD与保护无行为能力研究对象是相容的。